This is a single-arm, open-label and post-authorization study to evaluate the safety and
efficacy profile of sorafenib and to evaluate Child-Pugh status progression in subjects with
advanced HCC treated with sorafenib in Taiwan.
In a subgroup of patients (hand-foot skin reaction (HFSR) study subgroup), this study also
aims to test if topical corticosteroids as preventive counter-measure applied to hands and
feet for the first 3 weeks during sorafenib treatment reduce incidence and severity of HFSR
compared to a matching, corticosteroid-free cosmetic ointment, measured over the first 3 and
6 weeks of sorafenib treatment.